Background Palmoplantar psoriasis has significant physical and emotional impact on patients and can be difficult to
Introduction
Among patients with chronic plaque psoriasis, 6-17% have psoriasis affecting the palm and/or sole (i.e., palmoplantar psoriasis). [1] [2] [3] These patients may have localized palmoplantar psoriasis [3] [4] [5] or generalized psoriasis in addition to the palms and soles. Palmoplantar psoriasis is characterized by well-demarcated hyperkeratotic plaques that may or may not be associated with pustules. 5 Pure palmoplantar pustulosis is recognized as a subtype of palmoplantar psoriasis. 6 The relationship between palmoplantar types and subtypes is an area of significant interest and research especially relating to genetic similarities and differences and therapeutic options. [4] [5] [6] [7] [8] [9] Palmoplantar psoriasis is associated with greater physical disability than psoriasis without palm and sole involvement as well as overall greater disease severity, 10 ,11 more impairment of health-related quality of life and greater problems with mobility, self-care and usual activities, 4, 11 higher levels of burning, skin soreness 10 and pain. 12 Topical and conventional systemic therapies and phototherapy are often ineffective, difficult to administer and/or limited by adverse effects for individual patients. Although biologic therapies may be more effective, there are limited clinical data in well-controlled trials in populations with purely localized palmoplantar disease or in patients with psoriasis in other areas of their bodies and with significant concomitant palmoplantar involvement. [12] [13] [14] [15] [16] Ixekizumab (Taltz â ; Eli Lilly and Company, IN, USA) is a high-affinity monoclonal antibody that selectively targets interleukin (IL)-17A 17 and has been shown to be highly effective in the treatment of moderate-to-severe plaque psoriasis in three phase 3 studies (UNCOVER-1, 18 UNCOVER-2 19 and UNCOVER-3 19 ).
Using data integrated from these trials, we report the efficacy of ixekizumab in a subpopulation of patients with moderate-tosevere non-pustular hand and foot involvement and moderateto-severe plaque psoriasis at baseline. We evaluated the efficacy of ixekizumab compared with placebo and etanercept (Enbrel â ;
Amgen, CA, USA; Pfizer, NY, USA) after 12 weeks of treatment and the long-term maintenance of efficacy after 60 weeks of treatment.
Materials and methods

Study design
UNCOVER-1, UNCOVER-2 and UNCOVER-3 trials in patients with moderate-to-severe plaque psoriasis are registered with ClinicalTrials.gov (NCT01474512, NCT01597245 and NCT01646177, respectively). Details of the trial designs, blinding, sample size and randomization have been previously published. 18, 19 An investigational review board at each site reviewed and approved study protocols and informed consent forms, and all patients signed informed consent prior to undergoing study-related procedures.
Induction period Briefly, in the 12-week induction period in UNCOVER-1, 1296 total patients were randomly assigned 1 : 1 : 1 to receive subcutaneous placebo or a 160-mg starting dose of ixekizumab at week 0 followed by 80 mg ixekizumab every 2 weeks (IXEQ2W) or 4 weeks (IXEQ4W). In UNCOVER-2 and UNCOVER-3, 2570 total patients were randomly assigned 2 : 2 : 2 : 1 to: 160 mg ixekizumab starting dose followed by IXEQ2W or IXEQ4W, 50 mg etanercept twice weekly, or placebo.
period (weeks 12 through 60), per investigator and patient discretion, during which all patients received IXEQ4W for 48 weeks. This design provided cohorts of patients continuously treated with ixekizumab for 60 weeks (IXEQ2W/IXEQ4W and IXEQ4W/IXEQ4W).
Endpoints To assess the severity of psoriasis on the palms and soles, we used the Palmoplantar Psoriasis Area and Severity Index (PPASI), a composite score used specifically to evaluate palmoplantar plaque psoriasis. 15 PPASI is calculated as the sum of scores for erythema, induration and desquamation multiplied by a score for the extent of palm and sole area involved (range 0-72). A subset of patients with moderate-to-severe non-pustular palmoplantar psoriasis (defined as PPASI ≥8) 7, 20 at baseline was included in this analysis which evaluated at least 50%, 75% and 100% improvement in PPASI (PPASI 50, PPASI 75, PPASI 100) and the percent improvement in PPASI from baseline. We also evaluated the percent improvement in Psoriasis Area and Severity Index (PASI) and in Dermatology Life Quality Index (DLQI) score of 0 or 1 from baseline.
Patients
Patients aged 18 years or older were eligible for the three UNCOVER trials if they were candidates for phototherapy and/ or systemic therapy, had a confirmed diagnosis of chronic plaque psoriasis at least 6 months before baseline (random assignment to treatment), had ≥10% body surface area (BSA) involvement at both screening and baseline visits, had at least a moderate clinical severity as assessed by the clinician-rated measures of static Physician's Global Assessment (sPGA) score ≥3 and PASI score ≥12 at both screening and baseline and were candidates for phototherapy, systematic therapy or both. Patients with pustular forms of psoriasis were excluded. Complete lists of inclusion/exclusion criteria have been published previously. 18, 19 The current analysis includes only those patients with baseline palmoplantar involvement (PPASI ≥0) and focuses primarily on the subset with moderate-to-severe palmoplantar involvement (PPASI ≥8).
7,20
Statistical methods
The intent-to-treat (ITT) population in the week 0-12 induction period was defined as all randomly assigned patients, even if the patient did not take the assigned treatment, receive the correct treatment or otherwise follow protocol. In the induction period, treatment comparisons between proportions of patients with 50%, 75% and 100% PPASI improvement were made using a Cochran-Mantel-Haenszel test stratified by pooled centre for a study and stratified by study for integrated data, with nonresponder imputation for missing data. Percent improvement was analysed using mixed model for repeated measures (MMRM) for PPASI and PASI. Long-term extension population (UNCOVER-3) was defined as patients who received at least one dose of ixekizumab in the long-term extension period. Last observation carried forward was used for the long-term extension period. For PPASI responses, analysis was based on the ITT population with moderate-to-severe palmoplantar involvement.
Results
Population
A total of 1092 patients from UNCOVER-1, UNCOVER-2 and UNCOVER-3 had any palmoplantar psoriasis at baseline (PPASI ≥0), which represents 28.3% of the total study populations (N = 3866). Of these, 350 patients had moderate-to-severe palmoplantar psoriasis at baseline (PPASI ≥8), which represents 9.1% of the total study population. Baseline demographics and clinical characteristics for the moderate-to-severe palmoplantar psoriasis subgroup were generally balanced across the treatment groups (Table 1) . Overall, the mean baseline PPASI was approximately 20, the mean baseline PASI was approximately 24, the majority of these patients (>60%) had severe-to-very severe psoriasis (sPGA ≥4) and over 80% of the patients had nail psoriasis.
Efficacy at week 12 in UNCOVER-1, UNCOVER-2 and UNCOVER-3
Significantly greater mean percent improvements in PPASI (least squares mean) were observed at week 12 in patients receiving ixekizumab (approximately 80%) compared to those receiving placebo (28.1%) or etanercept (53.0%) ( Table 2 , P < 0.05 for all comparisons). Significant differences from placebo and etanercept were observed as early as week 1 (Fig. 1a) . Table 2 and Fig. 1b,c for results by treatment; P < 0.05 for all comparisons). Significantly greater proportions of patients receiving ixekizumab vs. placebo achieved a complete resolution of palmoplantar lesions (PPASI 100) (approximately 50% for combined ixekizumab doses vs. 8.2%) and more patients receiving IXEQ2W vs. etanercept achieved PPASI 100 (51.8% vs. 32.2%) (see Table 2 and Fig. 1d for results by treatment; P < 0.05 for all comparisons). Consistent with results on the palms and soles, at week 12, significantly greater mean percent improvements in PASI and a significantly greater proportion of patients with improvements in DLQI score of 0 or 1 were observed with ixekizumab vs. placebo or etanercept (Table 2 , P < 0.05 for all comparisons).
Efficacy through 60 weeks in UNCOVER-3
In UNCOVER-3, 8.5% of all patients had a PPASI ≥8 at baseline. Consistent with the results of week 12 integrated analysis of UNCOVER-1, UNCOVER-2 and UNCOVER-3 above, the UNCOVER-3 moderate-to-severe palmoplantar subgroup at week 12 reported similar proportions of ixekizumab-treated patients who achieved PPASI 50 (82.9% for combined ixekizumab doses), PPASI 75 (72.9% for combined ixekizumab doses) and PPASI 100 (48.6% for combined ixekizumab doses) (see Fig. 2a -c for results by treatment). At week 60, response rates either were maintained or showed improvement for PPASI Table 2 Patients with moderate-to-severe non-pustular palmoplantar involvement (baseline PPASI ≥8) and moderate-to-severe plaque psoriasis: outcomes at week 12 and week 60. *P < 0.05 vs. placebo, **P < 0.001 vs. placebo, a P < 0.05 for IXEQ4W vs. ETN and b P < 0.05 for IXEQ2W vs. ETN. †There was no comparator in the UNCOVER-3 long-term extension and efficacy is summarized by descriptive statistics. ‡IXEQ4W compared with IXEQ2W was not statistically significantly different for any of these variables. §All comparisons to ETN were based on the subpopulation of patients in studies that include etanercept (UNCOVER-2 and UNCOVER-3 only). DLQI, Dermatology Life Quality Index; ETN, etanercept; IXEQ4W, IXEQ2W, ixekizumab 80 mg every 4 or 2 weeks; LOCF, last observation carried forward; MMRM, mixed model for repeated measures; NRI, non-responder imputation; PASI, Psoriasis Area and Severity Index; PPASI, Palmoplantar Psoriasis Area and Severity Index; SD, standard deviation; SE, standard error; sPGA, static Physician's Global Assessment. Ixekizumab and palmoplantar plaque psoriasis 50 (approximately 72%), PPASI 75 (approximately 70%) and PPASI 100 (57.9% for IXEQ2W/IXEQ4W and 65.6% for IXEQ4W/IXEQ4W) ( Table 2 , Fig. 2a-c) .
Discussion
Here, we demonstrate a high efficacy of ixekizumab in treating non-pustular palmoplantar psoriasis in a population of patients with moderate-to-severe plaque psoriasis and significant palmoplantar involvement (PPASI ≥8) at baseline. Overall, ixekizumab treatment resulted in statistically significantly greater and more rapid improvements in psoriasis on the palms and soles than placebo and etanercept treatment through 12 weeks of treatment. This response was sustained through week 60. The majority of ixekizumab-treated patients achieved PPASI 75, and significantly greater mean percent improvements in PPASI compared to placebo and etanercept were observed as early as week 1. Half of the ixekizumab-treated patients had complete resolution of their palmoplantar psoriasis (PPASI 100) at week 12 and the percentage increased to 58% and 66% at week 60.
Consistent with other subpopulation analyses of clinical trials in moderate-to-severe plaque psoriasis, 13 approximately 30%
(n = 1092) of patients participating in the three phase 3 UNCOVER trials had any palmoplantar involvement (PPASI ≥0) at baseline and approximately 9% (n = 350) had a baseline PPASI ≥8 indicating moderate-to-severe disease. With 350 patients, this is one of the largest datasets published on patients with palmoplantar psoriasis. 12, 14, 15 At baseline, these patients had significant burden of disease. The majority had severe-tovery severe psoriasis (sPGA≥4), numerically higher baseline PASI (approximately 24 vs. approximately 20) and DLQI (15 vs. 12-13) and more patients had nail psoriasis (over 80% vs. 63%) than those of the overall study populations. A limitation to the analyses reported here is that it included only patients with moderate-to-severe plaque psoriasis who participated in the UNCOVER studies and who also had significant non-pustular palmoplantar involvement. Patients with pustular psoriasis, a difficult-to-treat variant of psoriasis, 16, 21 were
PalmarPlantar Quality-of-Life Index described by Farley and colleagues 4 were not assessed in the UNCOVER trials.
Despite these limitations, the current data support the effectiveness of IL-17A inhibition for treating non-pustular palmoplantar psoriasis. 5, 22, 23 Gottlieb et al. have reported the efficacy of another IL-17A antagonist, secukinumab, in patients with non-pustular palmoplantar psoriasis. In GESTURE, at week 16 patients receiving secukinumab 300 mg had nearly 55% reduction in PPASI and patients receiving secukinumab 150 mg had 35% reduction, whereas patients receiving placebo had only 4% reduction in PPASI. 15 Similar randomized, controlled, clinical trials that include patients with localized palmoplantar psoriasis (pustular and non-pustular) are necessary to fully evaluate the efficacy of ixekizumab and improvement in quality of life scores in this patient population.
Conclusion
Palmoplantar psoriasis has significant physical and emotional impact on patients and is traditionally recalcitrant to most therapies including systemic and biologic agents, with limited % PPASI 75 and (c) % PPASI 100 in patients with moderate-to-severe non-pustular palmoplantar involvement (PPASI ≥8) and moderateto-severe plaque psoriasis at baseline. *P < 0.05 vs. PBO, † P < 0.05 vs. ETN for weeks 0-12. In the long-term extension period in UNCOVER-3, efficacy is summarized by descriptive statistics, and PPASI responses were calculated based on the intent-to-treat population in the induction period. ETN, etanercept; IXEQ4W, IXEQ2W, ixekizumab 80 mg every 4 or 2 weeks; NRI, non-responder imputation; PBO, placebo; PPASI, Palmoplantar Psoriasis Area and Severity Index with 50%, 75% and 100% improvement in PPASI score (PPASI 50, PPASI 75, PPASI 100).
clinical data on the effectiveness of biologics for treating palmoplantar psoriasis. Using data integrated from three phase three trials 18, 19 in a subpopulation of patients with moderate-to-severe non-pustular palm and sole involvement and moderate-tosevere plaque psoriasis at baseline, we show that ixekizumab treatment results in rapid resolution of palmoplantar lesions in statistically significantly more patients than placebo or etanercept treatment, and these improvements are sustained with continued treatment.
